Future Market Insights’ updated report on the renal biomarker ecosystem highlights various opportunities and growth spots for the coming decade. As per the analysis, the renal biomarker market is set to account for a current valuation of US$ 1,541.2 million in 2024.
Following this pattern, demand could rise and equate to a market valuation of US$ 3,031.8 million, with a moderate CAGR of 7% by 2034.
Attributes
Details
Market Value for 2024
US$ 1,541.2 million
Market Value for 2034
US$ 3,031.8 million
Market Forecast CAGR for 2024 to 2034
7%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Historical Performance and Future Growth of the Renal Biomarker Market
Historical CAGR (2018 to 2023)
7.00%
Forecast CAGR (2024 to 2034)
7.00%
The renal biomarker market has exhibited robust historical performance, with a CAGR of 7.00% from 2018 to 2023. This steady growth can be attributed to the surge in the prevalence of kidney diseases, a boom in awareness about early diagnosis and treatment, and advancements in biomarker technologies.
The forecasted CAGR for the renal biomarker market from 2024 to 2034 remains at 7.00%, indicating continued growth momentum in the coming years. The forecast reflects the sustained demand for renal biomarkers as indispensable tools in clinical practice and research for the early detection, prognosis, and management of renal disorders.
Ongoing research and development efforts to discover novel biomarkers and improve diagnostic technologies are expected to contribute to market growth. The boom in adopting personalized medicine approaches and precision diagnostics will drive further investment in renal biomarker research and development, fueling market expansion over the forecast period.
Beacons to Guide the Renal Biomarker Market Forward
Continued innovation in biomarker discovery techniques, diagnostic assays, and imaging modalities is expected to propel the renal biomarker market forward.
Advancements such as high-throughput screening methods, omics technologies, and multiplexed assays enable the identification of new biomarkers with enhanced sensitivity and specificity, facilitating early disease detection and personalized treatment approaches.
The boom in focus on personalized medicine and precision diagnostics is set to propel the renal biomarker market.
Integrating biomarker data with clinical parameters enables more accurate risk stratification and treatment selection, driving the adoption of renal biomarkers in clinical practice.
Find your sweet spots for generating winning opportunities in this market.
Key Factors Hampering the Renal Biomarker Market
Insufficient validation studies may limit the clinical utility of biomarkers, leading to skepticism among healthcare providers and hindering their integration into routine clinical practice.
Reimbursement challenges and regulatory requirements pose significant barriers to commercializing and adopting renal biomarker tests.
The complex regulatory landscape and stringent reimbursement policies can prolong the time to market and raise development costs for biomarker-based diagnostics.
Category-wise Insights
The below section shows the leading segment. Based on the biomarker type, the functional biomarker segment is accounted to hold a market share of 53.9% in 2024. Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7% in 2024.
Category
Market Share in 2024
Functional Biomarker
53.9%
Enzyme Linked Immunosorbent Assay
46.7%
Functional Biomarker Segment to Hold a Significant Share in the Market
Based on biomarker type, the functional biomarker segment stands out, capturing a significant market share of 53.9%.
Functional biomarkers, such as serum creatinine and estimated glomerular filtration rate (eGFR), provide insights into kidney function and are essential for diagnosing and monitoring renal diseases. The widespread adoption reflects their critical role in clinical practice and research.
Enzyme Linked Immunosorbent Assay Segment to Hold a Dominant Share in the Market
Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7 % in 2024. The segment offers high sensitivity and specificity in detecting biomarkers in biological samples, making it a preferred choice for renal biomarker analysis.
The versatility and reliability contribute to its dominant position in the renal biomarker market, catering to the diagnostic needs of healthcare professionals and researchers alike.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative View of Adjacent Markets
This section compares the renal biomarker industry, the renal function test market, and the enzyme substrates market.
The surge in demand for renal function tests to diagnose and monitor CKD augments market growth as healthcare providers prioritize preventive measures and early intervention strategies to mitigate the rising incidence of kidney diseases.
Enzyme substrates are essential tools in drug discovery, biochemical assays, and biotechnology applications, facilitating the measurement of enzyme activity, drug screening, and target validation.
Renal Biomarker Market:
Attributes
Renal Biomarker Market
CAGR from 2024 to 2034
7%
Opportunity
Integrating artificial intelligence (AI) and machine learning algorithms into biomarker analysis and interpretation.
Key Trends
The surge in adoption of point-of-care testing (POCT) solutions for rapid and decentralized diagnosis of renal conditions.
Renal Function Test Market:
Attributes
Renal Function Test Market
CAGR from 2023 to 2033
5.5%
Opportunity
Expansion of home-based testing solutions for monitoring kidney function and managing chronic kidney diseases (CKD).
Key Trends
Adopting multi-marker or panel-based assays for comprehensive assessment of kidney function.
Enzyme Substrates Market:
Attributes
Enzyme Substrates Market
CAGR from 2023 to 2033
5.8%
Opportunity
An opportunity for the enzyme substrate market lies in expanding therapeutic applications beyond diagnostic use.
Key Trends
The development of novel substrate technologies with improved specificity, stability, and performance characteristics.
Country-wise Insights
The table describes the top five countries ranked by revenue, with the United Kingdom holding the top position. The United Kingdom dominates the renal biomarker market through its advanced healthcare infrastructure, robust research ecosystem, and extensive clinical expertise.
Renowned academic institutions, leading healthcare providers, and innovative biotechnology companies collaborate to drive biomarker research, development, and adoption, positioning the United Kingdom at the forefront of renal healthcare innovation.
Forecast CAGRs from 2024 to 2034
Countries
CAGR
The United States
7.8%
The United Kingdom
8.5%
France
6.7%
China
7.6%
India
6.9%
Extensive Usage of Renal Biomarkers Impresses the United States Market
In the United States, the renal biomarker market is utilized in clinical settings to detect, diagnose, and monitor kidney diseases such as chronic kidney disease (CKD), acute kidney injury (AKI), and renal transplant rejection.
Renal biomarkers are important in assessing kidney function, identifying patients at risk of kidney damage, and guiding treatment decisions. Renal biomarkers are extensively used in the research domain in academic institutions and biopharmaceutical companies for studying renal physiology, disease mechanisms, and therapeutic interventions.
Clinical Practice Boosts the Renal Biomarkers Market in the United Kingdom
Renal biomarkers are widely used in clinical practice to evaluate kidney function and diagnose renal disorders. General practitioners, nephrologists, and healthcare providers utilize renal biomarker tests for routine screening, disease monitoring, and risk stratification in patients with CKD, diabetes, etc.
Academic institutions and clinical laboratories employ renal biomarkers for translational research, biomarker discovery, and validation studies to improve renal healthcare outcomes and develop novel diagnostic and therapeutic strategies.
Academic Research Centers Rising in Popularity is Ensuring Market Growth in France
In France, renal biomarkers have extensive applications in clinical and research settings to address the growing burden of kidney diseases and improve patient care. Clinicians rely on renal biomarker tests to assess kidney function, diagnose renal disorders, and monitor disease progression in diverse patient populations.
Academic research centers and biotechnology companies utilize renal biomarkers to investigate disease mechanisms, identify therapeutic targets, and develop innovative diagnostic assays and therapeutic interventions for kidney diseases.
Developing Medical Centers in China Improves the Market
The renal biomarker market in China is predominantly utilized in clinical laboratories, hospitals, and medical centers for diagnosing and managing kidney diseases.
Renal biomarker tests are vital in evaluating kidney function, detecting renal damage, and guiding treatment decisions in patients with CKD, AKI, and other renal disorders.
In academic and research institutions, renal biomarkers are utilized for studying renal pathophysiology, biomarker discovery, and translational research to advance our understanding of kidney diseases and develop novel therapeutic approaches.
Rising Affluence of Renal Disorders Gives Rise to a Greater Demand for Renal Biomarkers
Similarly, in India, renal biomarkers are extensively used in clinical practice to assess kidney function, diagnose renal disorders, and monitor disease progression in patients with CKD, diabetes, and other renal conditions.
Renal biomarker tests are integral to routine healthcare screenings, specialty consultations, and preoperative assessments in hospitals and healthcare facilities nationwide.
Academic research institutes and biotechnology companies leverage renal biomarkers for conducting basic and translational research to improve renal healthcare outcomes and address the unmet needs of patients with kidney diseases.
Competitive Landscape
A mix of multinational corporations, biotechnology companies, and academic research institutions characterizes the competitive landscape of the renal biomarker market. The companies focus on research and development to innovate new biomarkers, improve diagnostic accuracy, and expand their market reach.
Partnerships, collaborations, and strategic acquisitions are common strategies players employ to strengthen their market position and capitalize on emerging opportunities in the renal biomarker market.
Some of the key developments are
In December 2022, Journey Biosciences, Inc. unveiled NaviDKD, a pioneering biomarker-based blood test designed to predict long-term kidney complications in individuals with diabetes. The groundbreaking screening technology offered an early warning system for the development of kidney damage in diabetic patients, addressing a critical need for proactive intervention and improved patient outcomes.
In March 2022, Renalytix plc introduced myIntelX, a state-of-the-art provider access portal aimed at enhancing access to KidneyIntelX prognostic testing. This blood-based biomarker test enabled more precise identification of type 2 diabetes patients at high risk of rapid kidney disease progression.
Key Coverage in the Renal Biomarker Industry Report
Adjacent Study on Renal Biomarker Market
Asia Pacific Renal Biomarker Market
Renal Biomarker Market Size, Current Insights, and Demographic Trends
Global Renal Biomarker Market Demand
Key Opportunities of the Global Renal Biomarker Market
What is the expected worth of the renal biomarker market in 2024?
As of 2024, the market for renal biomarkers is expected to be valued at US$ 1,541.2 million.
What is the market potential for renal biomarkers?
The renal biomarker market is projected to expand at a CAGR of 7% between 2024 and 2034.
Which biomarker type segment dominates the renal biomarker market?
The functional biomarker segment is projected to dominate the industry, with a market share of 53.9% in 2024.
What is the anticipated market value for renal biomarkers in 2034?
By 2034, the market value of the renal biomarker is expected to reach US$ 3,031.8 million.
Which country is likely to dominate the renal biomarker market?
The United Kingdom is likely the top-performing market, with a CAGR of 8.5%.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Biomarker
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Biomarker, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Biomarker, 2024 to 2034
5.3.1. Functional Biomarker
5.3.1.1. Serum Creatinine
5.3.1.2. Serum Cystatin C
5.3.1.3. Urine Albumin
5.3.2. Up-Regulated Proteins
5.3.2.1. Neutrophil Gelatinase-Associated Lipocalin
5.3.2.2. Kidney Injury Molecule-1
5.3.2.3. Interleukin-18
5.3.3. Others
5.4. Y-o-Y Growth Trend Analysis By Biomarker, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Biomarker, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Diagnostic Technique
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnostic Technique, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnostic Technique, 2024 to 2034
6.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
6.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
6.3.3. Colorimetric Assay
6.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
6.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
6.4. Y-o-Y Growth Trend Analysis By Diagnostic Technique, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Diagnostic Technique, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034
7.3.1. Diagnostic Labs
7.3.2. Outpatient Clinics
7.3.3. Research Centers
7.3.4. Hospitals
7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Biomarker
9.2.3. By Diagnostic Technique
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Biomarker
9.3.3. By Diagnostic Technique
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Biomarker
10.2.3. By Diagnostic Technique
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Biomarker
10.3.3. By Diagnostic Technique
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Biomarker
11.2.3. By Diagnostic Technique
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Biomarker
11.3.3. By Diagnostic Technique
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Biomarker
12.2.3. By Diagnostic Technique
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Biomarker
12.3.3. By Diagnostic Technique
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Biomarker
13.2.3. By Diagnostic Technique
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Biomarker
13.3.3. By Diagnostic Technique
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Biomarker
14.2.3. By Diagnostic Technique
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Biomarker
14.3.3. By Diagnostic Technique
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Biomarker
15.2.3. By Diagnostic Technique
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Biomarker
15.3.3. By Diagnostic Technique
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2023
16.1.2.1. By Biomarker
16.1.2.2. By Diagnostic Technique
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2023
16.2.2.1. By Biomarker
16.2.2.2. By Diagnostic Technique
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2023
16.3.2.1. By Biomarker
16.3.2.2. By Diagnostic Technique
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2023
16.4.2.1. By Biomarker
16.4.2.2. By Diagnostic Technique
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2023
16.5.2.1. By Biomarker
16.5.2.2. By Diagnostic Technique
16.5.2.3. By End User
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2023
16.6.2.1. By Biomarker
16.6.2.2. By Diagnostic Technique
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2023
16.7.2.1. By Biomarker
16.7.2.2. By Diagnostic Technique
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2023
16.8.2.1. By Biomarker
16.8.2.2. By Diagnostic Technique
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2023
16.9.2.1. By Biomarker
16.9.2.2. By Diagnostic Technique
16.9.2.3. By End User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2023
16.10.2.1. By Biomarker
16.10.2.2. By Diagnostic Technique
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2023
16.11.2.1. By Biomarker
16.11.2.2. By Diagnostic Technique
16.11.2.3. By End User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2023
16.12.2.1. By Biomarker
16.12.2.2. By Diagnostic Technique
16.12.2.3. By End User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2023
16.13.2.1. By Biomarker
16.13.2.2. By Diagnostic Technique
16.13.2.3. By End User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2023
16.14.2.1. By Biomarker
16.14.2.2. By Diagnostic Technique
16.14.2.3. By End User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2023
16.15.2.1. By Biomarker
16.15.2.2. By Diagnostic Technique
16.15.2.3. By End User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2023
16.16.2.1. By Biomarker
16.16.2.2. By Diagnostic Technique
16.16.2.3. By End User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2023
16.17.2.1. By Biomarker
16.17.2.2. By Diagnostic Technique
16.17.2.3. By End User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2023
16.18.2.1. By Biomarker
16.18.2.2. By Diagnostic Technique
16.18.2.3. By End User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2023
16.19.2.1. By Biomarker
16.19.2.2. By Diagnostic Technique
16.19.2.3. By End User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2023
16.20.2.1. By Biomarker
16.20.2.2. By Diagnostic Technique
16.20.2.3. By End User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2023
16.21.2.1. By Biomarker
16.21.2.2. By Diagnostic Technique
16.21.2.3. By End User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2023
16.22.2.1. By Biomarker
16.22.2.2. By Diagnostic Technique
16.22.2.3. By End User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2023
16.23.2.1. By Biomarker
16.23.2.2. By Diagnostic Technique
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Biomarker
17.3.3. By Diagnostic Technique
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Abbott Laboratories
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. BioPorto Diagnostics AS
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. F. Hoffmann-La Roche AG
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Thermo Fisher Scientific Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Nexelis (Pacific Biomarkers)
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. BioMérieux
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Sphingotec GmbH
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Randox Laboratories Ltd
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Siemens Healthineers AG
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Beckman Coulter Inc. (Danaher Corporation)
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Bio-Rad Laboratories Inc.
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 4: Global Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 5: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 6: North America Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 7: North America Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 8: North America Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 10: Latin America Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 11: Latin America Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Western Europe Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 15: Western Europe Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: East Asia Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 27: East Asia Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 28: East Asia Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Biomarker, 2019 to 2034
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Diagnostic Technique, 2019 to 2034
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2019 to 2034
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by End User, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 8: Global Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 9: Global Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 10: Global Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 11: Global Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 12: Global Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 13: Global Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 17: Global Market Attractiveness by Biomarker, 2024 to 2034
Figure 18: Global Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 19: Global Market Attractiveness by End User, 2024 to 2034
Figure 20: Global Market Attractiveness by Region, 2024 to 2034
Figure 21: North America Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 22: North America Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 23: North America Market Value (US$ Million) by End User, 2024 to 2034
Figure 24: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 28: North America Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 29: North America Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 30: North America Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 31: North America Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 37: North America Market Attractiveness by Biomarker, 2024 to 2034
Figure 38: North America Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 39: North America Market Attractiveness by End User, 2024 to 2034
Figure 40: North America Market Attractiveness by Country, 2024 to 2034
Figure 41: Latin America Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 42: Latin America Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 43: Latin America Market Value (US$ Million) by End User, 2024 to 2034
Figure 44: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 48: Latin America Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 51: Latin America Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 57: Latin America Market Attractiveness by Biomarker, 2024 to 2034
Figure 58: Latin America Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 59: Latin America Market Attractiveness by End User, 2024 to 2034
Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 61: Western Europe Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 62: Western Europe Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 63: Western Europe Market Value (US$ Million) by End User, 2024 to 2034
Figure 64: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 68: Western Europe Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 71: Western Europe Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 77: Western Europe Market Attractiveness by Biomarker, 2024 to 2034
Figure 78: Western Europe Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 79: Western Europe Market Attractiveness by End User, 2024 to 2034
Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 81: Eastern Europe Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 82: Eastern Europe Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2024 to 2034
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 97: Eastern Europe Market Attractiveness by Biomarker, 2024 to 2034
Figure 98: Eastern Europe Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 99: Eastern Europe Market Attractiveness by End User, 2024 to 2034
Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 101: South Asia and Pacific Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 102: South Asia and Pacific Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 103: South Asia and Pacific Market Value (US$ Million) by End User, 2024 to 2034
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 117: South Asia and Pacific Market Attractiveness by Biomarker, 2024 to 2034
Figure 118: South Asia and Pacific Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 119: South Asia and Pacific Market Attractiveness by End User, 2024 to 2034
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 121: East Asia Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 122: East Asia Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 123: East Asia Market Value (US$ Million) by End User, 2024 to 2034
Figure 124: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 128: East Asia Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 131: East Asia Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 137: East Asia Market Attractiveness by Biomarker, 2024 to 2034
Figure 138: East Asia Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 139: East Asia Market Attractiveness by End User, 2024 to 2034
Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 141: Middle East and Africa Market Value (US$ Million) by Biomarker, 2024 to 2034
Figure 142: Middle East and Africa Market Value (US$ Million) by Diagnostic Technique, 2024 to 2034
Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2024 to 2034
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Biomarker, 2019 to 2034
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Biomarker, 2024 to 2034
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Biomarker, 2024 to 2034
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Diagnostic Technique, 2019 to 2034
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Diagnostic Technique, 2024 to 2034
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Diagnostic Technique, 2024 to 2034
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 157: Middle East and Africa Market Attractiveness by Biomarker, 2024 to 2034
Figure 158: Middle East and Africa Market Attractiveness by Diagnostic Technique, 2024 to 2034
Figure 159: Middle East and Africa Market Attractiveness by End User, 2024 to 2034
Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
